



LETTER TO THE EDITOR

# Precise temporal regulation of *Dux* is important for embryo development

Cell Research (2019) 29:956–959; <https://doi.org/10.1038/s41422-019-0238-4>

Dear Editor,

Zygotic genome activation (ZGA) following fertilization is accomplished through a process termed the maternal-to-zygotic transition, during which the maternal RNAs and proteins are degraded and zygotic genome is transcriptionally activated.<sup>1</sup> In mice, minor ZGA occurs from S phase of the zygote to G1 phase of the two-cell (2C) embryo, while major ZGA takes place during the middle-to-late 2C stage with a burst of transcription of totipotent cleavage stage-specific genes and retrotransposons.<sup>2</sup> *Dux* has been recently identified and considered as a master inducer that regulates the ZGA process.<sup>3–5</sup> *Dux* can directly bind and robustly activate 2C stage-specific ZGA transcripts and convert mouse embryonic stem cells (mESCs) to a 2C-like state with unique features that resembles the 2C embryos.<sup>4</sup> Intriguingly, ~20% embryos with zygotic depletion of *Dux* unexpectedly reached morula or blastocyst stage even though defective ZGA program was detected.<sup>3</sup>

To determine whether *Dux* is a crucial factor for ZGA and embryo development, we generated a *Dux*-knockout (*Dux*-KO) mouse model using CRISPR/Cas9. Cas9 nuclease mRNA and two single guide RNAs (sgRNAs) targeting the macrosatellite tandem-array repeat region of *Dux* were injected into C57BL/6 zygotes. All injected embryos reached 2C stage and were transferred into oviduct of pseudo-pregnant recipients. F0 generation candidates with chimeric editing types were backcrossed with wild-type (WT) mice from the same genetic background. One of the F1 generation candidates carried large fragment deletion containing the second homeodomain of *Dux* (Fig. 1a). After backcrossing with WT individual again, the F1 candidate gave birth to heterozygous (Het) *Dux*<sup>+/-</sup> mice carrying the same mutation, indicating successful germline transmission. Homozygous *Dux*-KO mice were generated from heterozygous self-crossing, and the genotype was further confirmed by the third-generation long-read whole-genome sequencing, in which large fragment deletions in *LOC100504180* (*Duxf1*), *Dux* (*Duxf3*) and *Gm4981* (*Duxf4*) were observed. We also found short fragment deletions in *Gm10807* (*Duxf2*) and *Gm9919* (*Duxf5*) at the sgRNA targeting sites (Fig. 1a). Surprisingly, these homozygous *Dux*-KO mice could survive to adulthood, albeit they displayed a reduced frequency slightly deviated from a Mendelian distribution (Supplementary information, Fig. S1a). Notably, mating pairs of *Dux*-KO generated less offspring than WT pairs or Het pairs (Fig. 1b and Supplementary information, Fig. S1b). Thus, *Dux* depletion is not lethal, but it indeed leads to significantly decreased litter size. The phenotype, consistent with recent results,<sup>5</sup> strongly suggests that *Dux* is important but not essential for *in vivo* embryo development.

To further elucidate the effects of *Dux* depletion on embryos, maternal and zygotic (MZ) *Dux*-KO and WT embryos at zygotic, early 2C, middle 2C and late 2C stages were collected for single-cell RNA-seq (Smart-seq2). In agreement with published data<sup>7</sup> (Supplementary information, Fig. S1c), *Dux* mRNA and reads were detected only in WT embryos at early 2C stage, while absent at *Dux* locus in KO embryos (Supplementary information, Fig. S1d, e).

Moreover, *Dux*-KO embryos showed great similarity at transcriptional level to the KO embryos in recent report at late 2C stage<sup>6</sup> (Fig. 1c), further validating the successful knockout of *Dux*.


As *Dux* is transiently expressed at early 2C stage, we mainly focused on its impact at 2C stage. Thus, we defined 6145 2C stage ZGA genes that were upregulated in early, middle or late 2C stage compared to zygotic stage in WT embryos ( $\log_2FC > 1.5$  and  $FDR < 0.05$ , Supplementary information, Table S1). Dissecting different stages of 2C embryos revealed that *Dux* KO led to downregulation of MERVL and 129 ZGA genes (62.9% of downregulated genes) at early 2C stage, 213 ZGA genes (71.2%) at middle 2C stage, and 281 ZGA genes (78.1%) at late 2C stage, compared to WT 2C embryos ( $\log_2FC < -1.5$  and  $FDR < 0.05$ , Fig. 1d; Supplementary information, Fig. S1f–h, Tables 2–4). Intriguingly, these ZGA transcripts showed robust upregulation at late 2C stage compared to early 2C stage in the absence of *Dux*, indicating that the activation of these ZGA transcripts, although delayed, still took place in *Dux*-KO embryos (Fig. 1e, f; Supplementary information, Fig. S1i–k).

Thus, our single-cell RNA-seq results revealed that *Dux*-KO embryos at late 2C stage finally reached a state more similar to WT embryos at middle 2C stage than late 2C stage (Supplementary information, Fig. S1l). We speculated whether genetic compensation of *Dux* functional homologues triggered by *Dux* disruption as a mechanism expounded recently<sup>8</sup> might be responsible for the activation of these ZGA transcripts and viability of *Dux*-KO mice. However, the expression of *Gm4981* or *Duxbl* was not detected in *Dux*-KO embryos (Supplementary information, Fig. S1m).

Knockout of *Dux* resulted in delayed ZGA and decreased survivability of embryos. The phenotypic differences between *Dux*-KO individuals suggested that the potential compensatory factors may have to reach a threshold to support embryo development after *Dux* depletion as reported.<sup>9</sup> MERVL was found to generate chimeric transcripts with some 2C genes and its LTR (MT2) could promote the nearby 2C gene expression.<sup>10,11</sup> Several studies also demonstrated that MERVL expression could be detected as early as zygotic stage<sup>2,7,10</sup> (Fig. 1f), which is prior to endogenous expression of *Dux*. Remarkably, we found that MERVL was significantly upregulated at middle and late 2C stages in *Dux*-KO embryos, which is strongly correlated with the activation of some ZGA genes that generated chimeric transcripts with junctions to MERVL elements<sup>10</sup> (Fig. 1f and Supplementary information, Fig. S1n). In sum, our data demonstrate that *Dux* is an important factor for ZGA by enhancing but not initiating the expression of ZGA transcripts such as *Zscan4s*, *Tdpoz4*, *Usp17la*, *Zfp352* and MERVL.

To further determine the function of *Dux* in early embryo development, we injected the *in vitro* transcribed mRNA of *Dux*-EGFP (*Dux*-OE group) or EGFP (control group) into both blastomeres of 2C embryos (Fig. 1g and Supplementary information, Fig. S2a (left)) at late 2C stage when the endogenous *Dux* expression could not be detected already<sup>7</sup> (Supplementary information, Fig. S1d, e). We also injected RFP mRNA simultaneously in both groups for labeling and tracing. Different from the

Received: 12 June 2019 Accepted: 11 September 2019  
Published online: 7 October 2019



control group in which both EGFP and RFP were robustly expressed in the cytoplasm until blastocyst stage, Dux-EGFP expression specifically occurred in the nuclei and lasted a few hours, and most of Dux-EGFP was dramatically diminished in 8 h after injection (Fig. 1g). More interestingly, the injected 2C embryos were arrested mainly at four-cell (4C) stage (Fig. 1g, h),

similar to the phenomenon observed upon LINE1 knockdown that caused Dux upregulation as reported.<sup>12</sup> Immunostaining showed that the arrested embryos robustly expressed *Zscan4* and *MERVL*, the signatures of 2C embryo (Fig. 1i). To eliminate the artificial noise, we performed mRNA injection in only one blastomere of 2C embryos (Supplementary information, Fig. S2a (right)). The

**Fig. 1** **a** Schematic overview of *Dux* cluster locus in WT and *Dux*-KO mice, and distribution of third-generation long-read (30 kb) at the *Dux* cluster of *Dux*-KO mice. Red and blue arrowheads indicate targeting sites of sgRNAs. **b** Statistical analysis of litter size generated by WT, *Dux*-Het and *Dux*-KO mice. Each dot represents a single litter analyzed.  $***P < 0.001$ ; two-tailed Student's *t*-test. Center lines and error bars indicate means and SD, respectively. **c** Principal component analysis of WT and *Dux*-KO embryos from zygotic stage to 2C stage. e-2C, early 2C stage; m-2C, middle 2C stage; l-2C, late 2C stage. **d** Scatter plots of gene expression (left panel) and transposable element (TE) expression (right panel) in WT and *Dux*-KO embryos at early 2C (e-2C) stage.  $FC > 2$ ,  $FDR < 0.05$ . **e** Box plots of expression of 588 downregulated ZGA genes in WT and *Dux*-KO embryos from early to late 2C stages. e-2C, early 2C stage; m-2C, middle 2C stage; l-2C, late 2C stage.  $***P < 0.001$ ; Mann–Whitney–Wilcoxon two-sided test. The middle lines in the boxes represent medians. Box hinges indicate the twenty-fifth and seventy-fifth percentiles, and the whiskers indicate the hinge  $\pm 1.5 \times$  interquartile range. **f** Dot plots of MERVL-int expression in WT and *Dux*-KO embryos from zygotic to late 2C stages. Each dot represents an embryo. Zy, zygotic stage; e-2C, early 2C stage; m-2C, middle 2C stage; l-2C, late 2C stage.  $***P < 0.001$ ; two-tailed Student's *t*-test. Center lines and error bars indicate means and SD, respectively. **g** Development progression of embryos 4 h, 8 h, and 41 h after mRNA injection in 2 blastomeres of 2C embryos. h hours, *Dux*-OE group with mRNA mixture of *Dux*-EGFP and RFP (left panels), Ctrl control group with mRNA mixture of EGFP and RFP (right panels). Scale bars, 50  $\mu$ m. **h** Bar graph comparing the percentage of embryo at different developmental stages between *Dux*-OE and control groups 65 h after mRNA injection.  $*P < 0.05$ ,  $**P < 0.01$ ; two-tailed Student's *t*-test. Error bars indicate SD. **i** Immunofluorescent staining of *Dux*-OE (upper panels) and control (lower panels) embryos with 2-blastomere injection at 3C or 4C stage. Scale bars, 10  $\mu$ m. **j** Immunofluorescent staining of 1-blastomere-injected *Dux*-OE embryos at blastocyst stage. White dotted circles indicate the arrested blastomeres. Scale bars, 10  $\mu$ m. **k** Dot plots showing expression of *Dux* (upper panel) and MERVL-int (bottom panel) in *Dux*-OE and control embryos at early and late 4C stages. Each dot represents an injected embryo. e-4C, early 4C stage; l-4C, late 4C stage.  $***P < 0.001$ ; two-tailed Student's *t*-test. Center lines and error bars indicate means and SD, respectively. **l** Scatter plots of gene expression (left panel) and TE expression (right panel) in *Dux*-OE and control embryos at late 4C stage.  $FC > 2$ ,  $FDR < 0.05$ . **m** Statistics of *Dux*-EGFP expression hours in MG132-treated and -untreated embryos.  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ ; two-tailed Student's *t*-test. Error bars indicate SD

injected or non-injected blastomere showed no differences in developmental potential in the control group (Supplementary information, Fig. S2b, c). The blastomere injected with *Dux*-EGFP was mostly arrested after one cell cycle as monitored by the RFP signal and the other blastomere developed normally in *Dux*-OE group (Supplementary information, Fig. S2b, c). Immunostaining of such embryos at blastocyst stage showed that 2C-specific markers such as *Zscan4* and MERVL were robustly expressed in the arrested blastomeres, while the markers for blastocyst such as *Nanog* and *Cdx2* could only be detected in the blastocyst that developed from the non-injected blastomere (Fig. 1j). We could observe similar phenotype when injecting mRNA of *Dux*-EGFP or control EGFP into one blastomere of 4C embryos (Supplementary information, Fig. S2d, e). These results strongly suggest that prolonged expression of *Dux* in embryos significantly induced developmental arrest of blastomeres with 2C signatures.

To systematically study the transcriptional fluctuation caused by *Dux* expression *in vivo*, we collected the 2-blastomere-injected embryos of *Dux*-OE group and control group 6 h (early 4C stage) or 17 h (late 4C stage) after mRNA injection at late 2C stage. Transcriptional analysis revealed no significant differences between *Dux*-OE group and control group at early 4C stage (Supplementary information, Fig. S2f and Table S5). However, transcriptome changed violently in the *Dux*-OE embryos at late 4C stage (Supplementary information, Fig. S2g), with significant upregulation of *Dux*-related ZGA genes and retrotransposons (Fig. 1k, l; Supplementary information, Table S6). Collectively, these results demonstrate that *Dux* could promote the activation of some ZGA transcripts *in vivo*, while its prolonged expression would lead to developmental arrest and embryo death.

Both endogenous and exogenous expression of *Dux* last only a few hours in embryos. Especially when mRNA was injected into zygotes, *Dux*-EGFP was dramatically degraded within 3–5 h, showing no effect on development (Supplementary information, Fig. S3a–c and Table S7). This further demonstrated the importance of *Dux* degradation for embryo development. We speculated that there might be some mechanisms by which *Dux* protein is rapidly decomposed *in vivo*. Ubiquitin-proteasome system is a major intracellular protein degradation system during ZGA and early mouse embryo development.<sup>13</sup> Treatment of proteasome inhibitor MG132 greatly delayed the attenuation of *Dux*-EGFP signal in zygote, thus resulting in developmental arrest (Fig. 1m and Supplementary information, Fig. S3d). Moreover, overexpression of *Dux*-EGFP in NIH3T3 cell line followed by immunoprecipitation-mass spectrometry revealed that *Dux* not only interacted with ZGA-related proteins including *Zscan4* family, but also interacted with ubiquitin pathway-related proteins such

as *Uba52*, *Ubb*, *Ubc* and *Trim32*, as well as *Usp171a*, *Usp171e* and *Tdpoz5*, which were also induced by *Dux* in 2C embryos (Supplementary information, Fig. S3e and Table S8).

Overall, our study demonstrated that *Dux* is important but not essential for early embryo development by enhancing rather than initiating ZGA. Albeit *Dux*-KO mice can survive to adulthood, knockout of *Dux* led to delayed ZGA and decreased developmental potential of embryos. On the other hand, *Dux* indeed triggered ZGA program *in vivo*; however, its expression should be silenced not only by LINE1 to recruit Nucleolin/Kap1 complex at DNA level,<sup>12</sup> but also be degraded at both RNA and protein levels since prolonged activation of *Dux* severely impairs early embryo development. Exploring the mechanisms involved in *Dux* degradation may shed light on the deeper understanding of Facioscapulohumeral dystrophy (FSHD) caused by misexpression of *DUX4*,<sup>14</sup> the human orthologue gene of *Dux*. Together, our data indicates that the activation of *Dux* is non-essential but the degradation of *Dux* is strictly necessary for embryo development *in vivo*.

Note: When we prepared the manuscript for submission, one study published by Dr Yi Zhang's lab showed that *Dux* is not essential for ZGA.<sup>6</sup> The major conclusion of their study is basically the same as our *Dux* KO part, but our study also demonstrates that the degradation of *Dux* is important for proper embryo development.

#### DATA AVAILABILITY

All data sets that were generated in this study have been deposited in the Gene Expression Omnibus under accession number GSE134832.

#### ACKNOWLEDGEMENTS

We thank our colleagues in the laboratory for their assistance with the experiments and comments on the manuscript. This work was supported by the Ministry of Science and Technology of China (2018YFA0108900 and 2016YFA0100400), the National Natural Science Foundation of China (31671530, 81630035, 81871164, 31871486 and 31741028), and the Rising-Star Program of Shanghai Science and Technology Commission (18QA1404400). In addition, M.G. wants to thank the support from Ni Wang over the past years.

#### AUTHOR CONTRIBUTIONS

P.Y. and Y.W. designed the experiments. M.G. and J.Z. performed the experiments; Y. Zhang analyzed data. Y.B., J.X. and C.X. assisted with generation of knockout mice; X.K., Y. Zhao and Y.L. performed embryo microinjection and manipulation; Z.T., K.L. and J.L. assisted with generation of single cell RNA libraries. S.G., P.Y. and Y.W. conceived the project and provided mentoring. M.G. and Y.W. wrote the manuscript.

**ADDITIONAL INFORMATION**

**Supplementary information** accompanies this paper at <https://doi.org/10.1038/s41422-019-0238-4>.

**Competing interests:** The authors declare no competing interests.

Mingyue Guo<sup>1</sup>, Yanping Zhang<sup>1</sup>, Jianfeng Zhou<sup>1</sup>, Yan Bi<sup>1</sup>,  
Junqin Xu<sup>1</sup>, Ce Xu<sup>1</sup>, Xiaochen Kou<sup>1</sup>, Yanhong Zhao<sup>1</sup>, Yanhe Li<sup>1</sup>,  
Zhifen Tu<sup>1</sup>, Kuisheng Liu<sup>1</sup>, Jiaming Lin<sup>1</sup>, Peng Yang<sup>1</sup>,  
Shaorong Gao<sup>1</sup> and Yixuan Wang<sup>1</sup>

<sup>1</sup>*Clinical and Translational Research Center of Shanghai First  
Maternity and Infant Hospital, Shanghai Key Laboratory of Signaling  
and Disease Research, School of Life Sciences and Technology, Tongji  
University, 1239 Siping Road, Shanghai 200092, China*

*These authors contributed equally: Mingyue Guo, Yanping Zhang*

*Correspondence: Peng Yang (peng.yang@tongji.edu.cn) or*

*Shaorong Gao (gaoshaorong@tongji.edu.cn) or*

*Yixuan Wang (wangyixuan@tongji.edu.cn)*

**REFERENCES**

- Schulz, K. N. & Harrison, M. M. *Nat. Rev. Genet.* **20**, 221–234 (2019).
- Abe, K. I. et al. *Proc. Natl Acad. Sci. USA* **115**, E6780–E6788 (2018).
- De Iaco, A. et al. *Nat. Genet.* **49**, 941–945 (2017).
- Hendrickson, P. G. et al. *Nat. Genet.* **49**, 925–934 (2017).
- Whiddon, J. L., Langford, A. T., Wong, C. J., Zhong, J. W. & Tapscott, S. J. *Nat. Genet.* **49**, 935–940 (2017).
- Chen, Z. & Zhang, Y. *Nat. Genet.* **51**, 947–951 (2019).
- Deng, Q., Ramskold, D., Reinius, B. & Sandberg, R. *Science* **343**, 193–196 (2014).
- El-Brolosy, M. A. et al. *Nature* **568**, 193–197 (2019).
- Raj, A., Rifkin, S. A., Andersen, E. & van Oudenaarden, A. *Nature* **463**, 913–918 (2010).
- Macfarlan, T. S. et al. *Nature* **487**, 57–63 (2012).
- Zhang, W. et al. *Nucleic Acids Res.* pii: gkz594. <https://doi.org/10.1093/nar/gkz594> (2019).
- Percharde, M. et al. *Cell* **174**, 391–405 (2018).
- Higuchi, C. et al. *J. Reprod. Dev.* **64**, 65–74 (2018).
- Lek, A., Rahimov, F., Jones, P. L. & Kunkel, L. M. *Trends Mol. Med.* **21**, 295–306 (2015).